Author | Edward Chu, MD

September 18, 2018

In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.

February 15, 2018

This article reviews the critical issues of quality control and standardization of PHY906 and other herbal medicines, and highlights the importance of high-quality material for the conduct of preclinical and clinical studies, for cancer patients.

September 15, 2014

The issue of tumor heterogeneity is real, and it is present on several different levels. Without question, the presence of tumor heterogeneity has important clinical implications, and at this time, it represents a significant challenge to the success of cancer therapy.

February 15, 2014

It was originally hoped that the presence of mutations in KRAS and other related genes would provide an easy answer as to whether to administer anti-EGFR antibody therapy to a given metastatic colorectal cancer patient. However, in nature nothing is simple, and there are a number of issues that practicing clinicians should be made aware of.